
Dyne Therapeutics (DYN) Stock Forecast & Price Target
Dyne Therapeutics (DYN) Analyst Ratings
Bulls say
Dyne Therapeutics is a clinical-stage neuromuscular disease company with a unique platform technology called FORCE. Their pipeline includes several promising candidates targeting genetic neuromuscular diseases such as Duchenne muscular dystrophy and myotonic dystrophy. With well-documented governance and a strong management team, as well as a solid pipeline and a high probability of success for their leading candidate Z-rostudirsen, Dyne Therapeutics shows great potential for growth in the biotech sector.
Bears say
Dyne Therapeutics is a clinical-stage neuromuscular disease company that is focused on developing targeted therapeutics for genetically driven neuromuscular diseases. Their pipeline includes therapies for diseases with limited treatment options, and their technology has shown success in delivering safe and effective outcomes. However, the company still faces risks with safety and competition in the market, but their portfolio of programs and partnerships present a strong potential for future growth.
This aggregate rating is based on analysts' research of Dyne Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Dyne Therapeutics (DYN) Analyst Forecast & Price Prediction
Start investing in Dyne Therapeutics (DYN)
Order type
Buy in
Order amount
Est. shares
0 shares